Source: Annual Congress 2009 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Mazo, E. Sala, J. A. Barberà, J. Segovia, L. Molina, J. M. Arizón, M. Brand, D. Rosenberg, X. Llòria, D. Aubert, M. J. R. Pura (Bilbao, Palma de Mallorca, Barcelona, Madrid, Córdoba, Seville, Spain; Allschwil, Switzerland; Paris, France). Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain. Eur Respir J 2009; 34: Suppl. 53, 3894

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Nebulised Iloprost for pulmonary arterial hypertension associated with congenital heart disease: one centre's experience Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Pulmonary arterial hypertension related with congenital heart disease (PAH r-CHD): a retrospective study of 21 patients Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease Source: Eur Respir Rev 2011; 20: 236-242 Year: 2011 Efficacy of exercise training in congenital heart disease associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012